Compare ADMA Biologics Inc (ADMA) vs Advanced Micro Devices (AMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs Advanced Micro Devices — how do they compare? ADMA Biologics Inc trades at $9.88 (market cap $2.18B), while Advanced Micro Devices trades at $476.67 (market cap $766.54B). The key difference: Advanced Micro Devices is far larger — about 351.6× ADMA Biologics Inc's market cap, and Advanced Micro Devices is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | AMD | |
|---|---|---|
Market Cap | $2.18B | $766.54B |
Sector | Health | Technology |
52-Week High | $20.38 | $580.91 |
52-Week Low | $7.60 | $151.14 |
Enterprise Value | $2.25B | $757.71B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.90, down 1.59% today, with strong profitability metrics including 64.71% gross margin and 41.9% ROE. Technical indicators show a bullish trend with support at $9-10, though RSI levels suggest overbought conditions. Recent earnings show mixed results with Q4 2025 beating expectations but Q1 and Q2 2026 missing estimates. The stock faces significant legal headwinds with multiple securities fraud lawsuits filed against the company.
Despite strong fundamentals and bullish analyst consensus (88.9% buy ratings), ADMA faces substantial legal risks from ongoing securities litigation that could impact shareholder value. The company's solid profit margins and growth trajectory provide upside potential, but investors should carefully weigh litigation risks against fundamental strength.
AMD trades at $474.32, down 1.87% on the day, with a bearish technical signal but strong fundamental momentum. The stock shows elevated valuation metrics (P/E 119.79, P/S 18.75) despite impressive revenue growth to $34.64B in 2025 and consistent earnings beats. Analyst consensus remains strongly bullish with a $615.11 price target, while recent news highlights AMD's positioning in the competitive AI semiconductor market.
AMD presents a growth story driven by AI and data center demand, with projected revenue reaching $41.3B in 2026. However, high valuations and intense competition from NVIDIA represent significant risks. The stock offers substantial upside to analyst targets but requires careful monitoring of execution and market share dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Advanced Micro Devices
Advanced Micro Devices, Inc. (AMD) produces semiconductor products and devices. The Company offers products such as microprocessors, embedded microprocessors, chipsets, graphics, video and multimedia products and supplies it to third-party foundries, as well as provides assembling, testing, and packaging services. AMD serves customers worldwide.
Read more on AMD →
